Brean Murray Starts Sinovac Biotech Ltd. (SVA) at Buy
More News related to SVA
- Sernova Corp.'s Diabetes Technology Featured at International Congress of the Transplantation Society and on CTV National News
- Sernova Corp.'s Diabetes Technology Featured at International Congress of the Transplantation Society and on CTV National News
- Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
- Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
- Sinovac to Host Conference Call to Report Second Quarter 2008 Financial Results
More News related to New Coverage
- ThinkPanmure Starts ON Semiconductor (ONNN) at Buy
- Merrill Lynch Initiates Coverage on Regency Energy Partners (RGNC) with a Neutral
- Morgan Stanley Starts Elan (ELN) at Overweight
- Morgan Keegan Resumes Petrohawk Energy (HK) at Outperform
- Raymond James Starts CA Inc. (CA) at Outperform
Brean Murray initiates coveage on Sinovac Biotech Ltd. (AMEX: SVA) with a Buy rating and $5 price target.
The firm said, "We believe Sinovac, a leading specialist in the development and production of hepatitis and flu vaccines in China, is well positioned to benefit from the rapidly expanding Chinese vaccine market, which is supported by the country's growing population and personal wealth, greater access to healthcare, and a commitment by the government to combat popular infectious diseases."
The firm notes the company's major product, Healive, is the No. 1 selling hepatisi A vaccine in China, and accounts for about 33% of the total hepatisi A vaccine market.
Related Categories
New CoverageStocks Mentioned
-0.01Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
